drugset / Trial / NCT04171141
Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.
Non-randomizedSequentialOpen-labelTreatment
Summary
A phase 1, open-label, dose escalation and expansion study of PF-07062119 in patients with selected advanced or metastatic gastrointestinal tumors
Timeline
- Start
- 2019-11-19
- Primary completion
- 2023-11-28
- Completion
- 2023-11-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | PF-07062119 | Unknown | — | — |
| Subject | Sasanlimab | Monoclonal antibody | — | — |